Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced results from the X-VeRT trial, demonstrating once-daily rivaroxaban may be an alternative to vitamin K antagonists in treating and reducing the risk of blood clots in non-valvular atrial fibrillation patients undergoing elective cardioversion, a common medical procedure to reset the heartbeat back to a regular rhythm.Â